HOME >> MEDICINE >> NEWS
Mount Sinai Researchers present findings on treatments for prostate and breast cancer

Researchers from the Department of Radiation Oncology and the Milton and Caroll Petrie Department of Urology at Mount Sinai School of Medicine are presenting findings from ten studies of prostate and breast cancer treatments at the 47th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), October 16-20, 2005, in Denver, Colorado.

The research results being detailed:

  • A higher incidence of ATM gene variants in African American Women. (Lead author: G. Fan)
  • A significant percentage (at seven years minimum) of men with normal pre-treatment sexual function were able to experience a high rate of erectile function as quantified by the IIEF-5 and physician assigned a scoring system. (Lead author: J.A. Cesaretti)
  • Possession of a mutated ATM gene is associated with the development of grade 2 proctitis for patients treated with 125I brachytherapy. (Lead author: J.A. Cesaretti)
  • A specific genetic alteration is predictive for the development of late adverse radiotherapy responses among breast cancer patients treated with adjuvant radiation therapy. (Lead author: A.Y. Ho)
  • Prostate brachytherapy is generally well tolerated and appears to be safe in patients with a history of IBD. (Lead author: C.A. Peters)
  • If biologically effective doses can be achieved, excellent long-term biochemical and local control rates can be realized. (Lead author: R.G. Stock)
  • Overall long term morbidity associated with brachytherapy with or without HT and EBRT is low. (Lead author: N.N. Stone)
  • Insight into patient's erectile function post-brachytherapy can b well-assessed using the Mount Sinai Erectile Function Scale, along with, the International Index of Erectile Function-15. (Lead author: T.M. Zagar)
  • Ultrasound-guided brachytherapy is a reasonable salvage option for patients with biopsy proven biochemical recurrence following definitive external beam radiation therapy. (Lead author:
    '"/>


Contact: Mount Sinai Press Office
newsmedia@mssm.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
18-Oct-2005


Page: 1 2

Related medicine news :

1. New breakthrough treatment for spinal cancer patients at Mount Sinai
2. Mount Sinai and EXACT Sciences announce study results on study stool DNA testing for colon cancer
3. Wiley to assume publication of Mount Sinai Journal of Medicine
4. Mount Sinai researcher finds drinking water safe to drink
5. The Mount Sinai Medical Center recognized for excellence in bariatric surgery
6. Mount Sinai Global Health Center receives $1M grant
7. Mount Sinai School of Medicine receives prestigious AAMC Grant for Chronic Illness Care education
8. Mount Sinai and YAI/NIPD Network join forces to further quality of care for people with autism
9. Mount Sinai launches combination therapy trial to treat Relapsing-Remitting Multiple Sclerosis
10. CNIC commits 5 million Euros to the Mount Sinai School of Medicine
11. Mount Sinai expands cutting-edge molecular testing

Post Your Comments:
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 (HealthDay ... (IVF) -- the incubation of embryos in a laboratory dish ... vagina, new research suggests. Scientists from the United States ... sharply cut costs for pricey IVF procedures among certain women. ... who don,t live near big-city assisted reproduction centers, the researchers ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... officials on Monday officially tightened guidelines for health workers treating ... exposure and use of a respirator at all times. ... issue the tougher rules after two Dallas nurses contracted Ebola ... United States, Liberian national Thomas Eric Duncan. Nina Pham is ...
(Date:10/20/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... is the must-have source of thousands of facts, figures ... 72 countries and 68 medical sector forecast categories the ... you with global, regional and national views on the ... future outlook. , The report gives you data for ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Allegheny General ... procedure that enables physicians to repair a damaged mitral ... MitraClip system, developed by Abbott Vascular ... a progressive and life-threatening condition in which the heart’s ... to flow backward from the heart’s left ventricle into ...
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
(Date:10/22/2014)...   Surefire Medical , Inc., the developer of ... targeted delivery of embolization agents in minimally invasive direct-to-tumor ... John R. Daniels , MD of the University of ... Steven C. Katz , MD of the Roger ... Board (SAB).    "The role of the ...
(Date:10/22/2014)... and AUSTIN, Texas ... and PureMHC LLC today announced they have entered ... novel antibody-based immunotherapies designed to target cancers. ... phosphorylated peptides displayed on the surfaces of tumor ... tumor targets (PTTs), derived from proteins that play ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
Cached News: